Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF

NCT04554056 | Completed Phase 2

• 1 other identifier: MW05-2020-CP301
• Study Type: interventional
• Target: 586
• Locations: 1 country
• Sites: 1

Brief Summary

In the study, subjects will scheduled to undergo four 21-days cycles of chemotherapy treatment. Three group were treated with MW05 300 μg/kg or MW05 500 μg/kg or PEG-rhG-CSF 100 μg/kg on the 3th day of each cycle randomized 1:1:1 . The dose of the experimental drug MW05 in phase III were determined by independent data monitoring committee (IDMC) according to the efficacy and safety of phase II. Subjects were randomly divided into two groups 1:1 to received either MW05 or PEG-rhG-CSF(100 μg/kg) on the 3th day of each chemotherapy cycle.

Conditions

Breast Cancer Female

Outcome Measures

Primary Outcomes (1)

• The primary objective of this study will be to evaluate the efficacy of MW05 pre-filled syringe as compared to PEG-rhG-CSF standard dosing (6 mg) in the first chemotherapy cycle.

  The primary endpoint will be the duration of grade 4 (severe) neutropenia - the number of days in which the patient has had an absolute neutrophil count (ANC \<0.5 x 109/L) observed in chemotherapy cycle 1.

  in cycle 1（each cycle is 21 days）

Secondary Outcomes (6)

• The duration of grade 4 neutropenia in cycle 2~4 assessed by ANC（ANC < 0.5 × 109/L）

  in cycles 2-4, in overall 3 cycles（each cycle is 21 days）

• The incidence of grade 4 neutropenia in cycle 1~4 assessed by ANC（ANC < 0.5 × 109/L）

  through study completion, in overall 4 cycles（each cycle is 21 days）

• The incidence of grade 3 or 4 neutropenia in cycle 1~4 assessed by ANC（ANC < 1.0 × 109/L and ANC < 0.5 × 109/L, respectively）

  through study completion, in overall 4 cycles（each cycle is 21 days）

• The duration of grade 3 or 4 neutropenia In cycle 1~4 assessed by ANC（ANC < 1.0 × 109/L and ANC < 0.5 × 109/L, respectively）

  through study completion, in overall 4 cycles（each cycle is 21 days）

• Incidence of febrile neutropenia (FN) (defined as ANC < 1.0×109/L; a single measurement of body temperature > 38.3°C or a temperature ≥ 38.0 °C sustained over 1 h)

  through study completion, in overall 4 cycles（each cycle is 21 days）

Study Arms (3)

MW05 300μg/kg

EXPERIMENTAL

Subjects will receive MW05(300 μg/kg s.c.) on day 3 of each cycle (6\~10 a.m.)

Drug: MW05

MW05 500μg/kg

EXPERIMENTAL

Subjects will receive MW05(500 μg/kg s.c.) on day 3 of each cycle (6\~10 a.m.)

Drug: MW05

PEG-rhG-CSF

ACTIVE COMPARATOR

Subjects will receive PEG-rhG-CSF(100 μg/kg s.c.) on day 3 of each cycle (6\~10 a.m.)

Drug: PEG-rhG-CSF

Interventions

MW05 DRUG

Recombinant (yeast secreted) human serum albumin-human granulocyte colony stimulating factor (I) fusion protein injection

Also known as: MW05 injection

MW05 300μg/kg; MW05 500μg/kg

PEG-rhG-CSF DRUG

PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor

Also known as: PEG-rhG-CSF injection

PEG-rhG-CSF

Eligibility Criteria

• Age: 18 Years - 70 Years
• Gender Eligibility Details: Female patients with breast cancer who require chemotherapy and are planned to receive at least 4 cycles of TC chemotherapy, namely Docetaxel 75 mg/m2 and Cyclophosphamide 600 mg/m2
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• ～70 years old female(including threshold)
• Diagnosed with breast cancer .
• Weight≥45kg.
• Patients planned to receive TC chemotherapy.
• ECOG ≤ 1
• Estimated survival time ≥ 3 months, and could received at least 4 cycles chemotherapy treatment.
• Have suitable organs and hematopoietic function
• ECG examination is normal or abnormal has no clinical significance.
• B-ultrasound examination of abdomen showed no obvious abnormality of spleen.
• Willing to sign the informed consent form and able to comply with protocol requirements.
• Non-menopausal or non-surgically sterilized female subjects, the blood pregnancy test results must be negative at the time of screening, and within at least 3 months from the signing of the informed consent form to the end of the last administration, consent to abstinence or the use of effective contraceptive methods.

You may not qualify if:

• History of other malignant tumors (skin basal cell carcinoma, skin squamous cell carcinoma and / or carcinoma in situ after radical resection can be included in the group after being cured for more than 5 years)
• Primary hematological diseases, including but not limited to myelodysplastic syndrome, aplastic anemia, sickle cell anemia and other hematological diseases that affect bone marrow hematopoiesis.
• With known central nervous system metastasis or suspected central nervous system metastasis based on clinical manifestations.
• With previous history of bone marrow transplantation and / or stem cell transplantation.
• Currently uncontrolled infections or have received systematic anti-infective therapy within 72 hours before randomization.
• Serious chronic diseases of important organs such as kidney and liver.
• Severe heart disease, including but not limited to:history of congestive heart failure (New York College of Cardiology \[NYHA\] II or higher heart disease)Angina pectoris that needs to be treated with anti-angina pectoris drugsUncontrollable hypertension (systolic blood pressure ≥ 180 mmHg and / or diastolic blood pressure ≥ 100 mmHg)Arrhythmias requiring drug treatment
• Severe diabetes (such as fundus disease or diabetic foot), or blood sugar is still not well controlled after active treatment.
• Surgery within 2 weeks before chemotherapy or radiotherapy within 4 weeks (except for patients whose physical condition has recovered and can accept the relevant procedures of this study, as determined by the researchers)
• Adverse reactions from previous treatments failed to recover to CTCAE v5.0 score ≤ 1 (except for alopecia and other toxic reactions that researchers believe do not affect the safety of this chemotherapy)
• According to the researchers, there are serious risks to the safety of patients or concomitant diseases that affect the completion of the study.
• Participated in clinical trials of any other drugs within 4 weeks.
• Received the same efficacy drugs(such as PEG-rhG-CSF or rhG-CSF, etc.) are still in 5 half-lives or within 28 days (whichever is shorter).
• With allergic disease or allergic constitution, and who have previously been allergic to any drug or its components in this trial.
• Active hepatitis B (HBsAg positive and HBV-DNA copy number greater than the normal limit) and / or active hepatitis C (hepatitis C virus antibody positive and HCV-RNA copy number greater than the normal limit) and / or human immunodeficiency virus antibody positive and / or Treponema pallidum antibody.

Sponsors & Collaborators

• Mabwell (Shanghai) Bioscience Co., Ltd.: lead

Study Sites (1)

Fudan University Affiliated Cancer Hospital

Shanghai, China

Location

MeSH Terms

Interventions

pegylated granulocyte colony-stimulating factor

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 27, 2020
• First Posted: September 18, 2020
• Study Start: September 21, 2020
• Primary Completion: August 20, 2022
• Study Completion: November 5, 2022
• Last Updated: December 2, 2022

Record last verified: 2022-12

Locations

CN (1)